vorapaxar and Vascular-Diseases

Protease-activated receptor 1 (PAR1) and toll-like receptors (TLRs) are inflammatory mediators contributing to atherogenesis and atherothrombosis. Vorapaxar, which selectively antagonizes PAR1-signaling, is an approved, add-on antiplatelet therapy for secondary prevention. The non-hemostatic, platelet-independent, pleiotropic effects of vorapaxar have not yet been studied.. PAR1 inhibition with vorapaxar may be effective in reducing residual thrombo-inflammatory event risk in patients with atherosclerosis independent of its effect on platelets.

Topics: Animals; Apolipoproteins E; Atherosclerosis; Female; Humans; Inflammation; Intercellular Adhesion Molecule-1; Lactones; Male; Mice; Mice, Knockout; Myocardium; Platelet Aggregation; Pyridines; Receptor, PAR-1; Thrombin; Toll-Like Receptor 2; Toll-Like Receptor 4; Vascular Cell Adhesion Molecule-1; Vascular Diseases